Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atezolizumab · 1 trial · 1 indication
Disease control rate (DCR) will be measured by the proportion of patients who had either stable disease (SD) for at least 16 weeks or confirmed partial response (PR) or complete response (CR) according to RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| TTFields + atezolizumab + gemcitabine and nab-paclitaxel | EXPERIMENTAL | Patients receive TTFields at 150 kHzconcomitant with atezolizumab, gemcitabine and nab-paclitaxel until disease progression or loss of clinical benefit. |
| Name | Type | Description |
|---|---|---|
| Tumor Treating Fields | DEVICE | The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the patient by means of insulated transducer arrays. The NovoTTF-200T produces TTFields that exert electric forces intended to disrupt cancer cell division. TTFields at 150 kHz application will be continuous for at least 18 hours a day on average. TTFields will be continued until disease progression according to RECISTv1.1 or loss of clinical benefit. |
| Atezolizumab | DRUG | Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution. Atezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit. |
| Gemcitabine | DRUG | Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion. Gemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit. |
| nab-paclitaxel | DRUG | Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion. Nab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit. |
Inclusion Criteria: 1. Signed Informed Consent Form for the study protocol. 2. 18 years of age and older at the time of signing Informed Consent Form. 3. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1. 4. Histologically or cytologically confirmed de-novo diagnosis of metastatic...
Atezolizumab is being studied as a first-line treatment for metastatic pancreatic ductal adenocarcinoma, given together with gemcitabine and nab-paclitaxel. The investigational combination also includes Tumor Treating Fields, a therapy delivered through the EF-39 PANOVA-4 study. This is an investigational use, and the drug is not approved for this indication.
Atezolizumab is a small molecule that targets PD-L1, a protein that helps cancer cells evade the immune system. By blocking PD-L1, the drug aims to restore the immune system's ability to recognize and attack cancer cells. In the PANOVA-4 trial, it is combined with chemotherapy and Tumor Treating Fields for metastatic pancreatic ductal adenocarcinoma.
Atezolizumab is being developed by NovoCure Limited, a company traded on the stock exchange under the ticker NVCR. The drug is being evaluated in the PANOVA-4 clinical trial for metastatic pancreatic ductal adenocarcinoma, where it is given alongside gemcitabine, nab-paclitaxel, and Tumor Treating Fields.
Atezolizumab is in Phase 2 clinical development for metastatic pancreatic ductal adenocarcinoma. The Phase 2 trial, known as EF-39 PANOVA-4, has been completed. The study enrolled 84 participants and was not randomized or double-blinded, and it did not use a control group.
Atezolizumab is being studied in the clinical trial NCT06390059, titled EF-39 PANOVA-4. This Phase 2 study evaluated the drug in combination with gemcitabine, nab-paclitaxel, and Tumor Treating Fields as first-line treatment for metastatic pancreatic ductal adenocarcinoma. The trial has been completed and enrolled 84 participants across Czechia, Germany, Spain, and Switzerland.
Atezolizumab is the sole name provided for this drug, with no alternative names listed. It is an investigational small molecule being developed by NovoCure Limited for metastatic pancreatic ductal adenocarcinoma. The drug is currently in Phase 2 clinical development, and no other names have been associated with it in the available information.